VIDEO PILLOLE

Alfa-sinucleina, neuroinfiammazione e neurodegenerazione della malattia di Parkinson

Dr. Luca Magistrelli

Alfa-sinucleina, neuroinfiammazione e neurodegenerazione della malattia di Parkinson

Dr. Alessio Di Fonzo

La patogenesi delle fluttuazioni motorie: il ruolo della Levodopa e della sua ottimizzazione

Dr.ssa Fabiana Colucci

Identificare precocemente e gestire le fluttuazioni motorie e non-motorie: il ruolo degli iCOMT

Dr.ssa Micol Avenali

Differenze di genere nella patogenesi e gestione delle fluttuazioni motorie e non-motorie

Dr.ssa Maria Laura Ester Bianchi

Le fluttuazioni residue nei pazienti sottoposti a STN-DBS o terapia infusionale: il ruolo degli iCOMT

Dr. Carlo Alberto Artusi

CASI CLINICI

  1. Pathological Pathways and Alpha-Synuclein in Parkinson’s Disease: A View from the Periphery
  2. Adjunctive Therapies in Parkinson’s Disease: How to Choose the Best Treatment Strategy Approach
  3. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson’s Disease
  4. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study
  5. Deep Brain Stimulation Selection Criteria for Parkinson’s Disease: Time to Go beyond CAPSIT-PD
  6. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach
  7. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson’s Disease
  8. Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/ spreading mouse model of Parkinson’s disease
  9. Alpha Synuclein: Neurodegeneration and Inflammation
  10. Medical Management of Parkinson’s Disease after Initiation of Deep Brain Stimulation
  11. Sex differences in movement disorders
  12. Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa
  13. Gender and non motor fluctuations in Parkinson’s disease: A prospective study
  14. “On-State” Freezing of Gait: Insights and Treatment With Levodopa Intestinal Gel Infusion
  15. Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?
  16. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
  17. An Update on the Critical Role of α‐Synuclein in Parkinson’s Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels
  18. Striatal glutamatergic hyperactivity in Parkinson’s disease
  19. The relevance of gender in Parkinson’s disease: a review
  20. The real‐life effect of catechol‐O‐methyltransferase inhibition on non‐motor symptoms in levodopa‐treated Parkinson’s disease: opicapone versus entacapone